ABBREVIATIONSHDFNhemolytic disease of the fetus and newbornIUFDintrauterine fetal demiseIUT(s)intrauterine transfusion(s)MCA‐PSVmiddle cerebral artery peak systolic velocityMoMmultiples of the medianNICUneonatal intensive care unitNIPTnoninvasive prenatal testingTPEtherapeutic plasma exchangeThe antibodies most commonly associated with severe hemolytic disease of the fetus and newborn (HDFN) and necessitating intrauterine red blood cell (RBC) transfusion are anti‐D, anti‐c, anti‐K, and anti‐E. The current practice of RhIG prophylaxis for D– women during pregnancy has decreased the incidence of D‐associated HDFN to 0.1% to 0.6%. Maternal alloimmunization to certain non‐D antigens, most notably c and E antigens, and minor RBC antigens such as Kell, Duffy, Kidd, and MNS antigens are now more common causes of HDFN because no prophylactic immune globulins are available. In this retrospective case series, we report our experience with five patients diagnosed with HDFN due to maternal RBC alloimmunization who were managed with a combined immunomodulatory regimen consisting of therapeutic plasma exchange (TPE) and intravenous immune globulin (IVIG) in early gestation, followed by multiple RBC intrauterine transfusions (IUTs) later in gestation (at gestational age > 20 weeks). In addition to providing insight into the treatment process and efficacy, this information may be especially important for patients with limited treatment options due to potential contraindications and/or unavailability of
Transfusion – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera